Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23593602 | 1.00 | KDM1A (0.38) | KDM1AKDM4EHPGDPDE4DCD38 | |
| SCHEMBL23593521 | 1.00 | KDM1A (0.38) | KDM1AKDM4EHPGDPDE4DCD38 | |
| SCHEMBL23593536 | 1.00 | KDM1A (0.38) | KDM1AKDM4EHPGDPDE4DCD38 | |
| SCHEMBL23578759 | 1.00 | KDM1A (0.38) | KDM1AKDM4EHPGDPDE4DCD38 | |
| SCHEMBL23593515 | 0.89 | ALDH1A1 (0.43) | KDM4EHPGDALDH1A1 | |
| SCHEMBL23578666 | 0.87 | KDM1A (0.41) | KDM1APDE4DSUV39H2RBP4TTR | |
| SCHEMBL23579154 | 0.87 | KDM1A (0.41) | KDM1APDE4DSUV39H2RBP4TTR | |
| SCHEMBL23578665 | 0.87 | KDM1A (0.41) | KDM1APDE4DSUV39H2RBP4TTR | |
| SCHEMBL23578720 | 0.87 | KDM1A (0.41) | KDM1APDE4DSUV39H2RBP4TTR | |
| SCHEMBL23579429 | 0.87 | KDM1A (0.41) | KDM1APDE4DSUV39H2RBP4TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12172983-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230056541-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20230056541-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20230026209-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-20230026209-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
| EP-4081515-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | Blueprint Medicines Corporation (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115135642-A | Inhibitors of mutant forms of EGFR | 缆图药品公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2021133809-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133809-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056541-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | KDM1A 3493/4885KDM4E 3171/4885HPGD 3657/4885 |
| US-20230026209-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | KDM1A 3493/4885KDM4E 3171/4885HPGD 3657/4885 |
| US-11718602-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | KDM1A 3493/4885KDM4E 3171/4885HPGD 3657/4885 |
| US-12172983-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | KDM1A 3493/4885KDM4E 3171/4885HPGD 3657/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | KDM1A 3493/4885KDM4E 3171/4885HPGD 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.